Compare Consumer Discretionary Select Sector SPDR Fund (XLY) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consumer Discretionary Select Sector SPDR Fund vs Zoetis Inc — how do they compare? Consumer Discretionary Select Sector SPDR Fund trades at $112.79, while Zoetis Inc trades at $73.83 (market cap $30.29B). The key difference: Zoetis Inc pays a 2.89% dividend while Consumer Discretionary Select Sector SPDR Fund pays none, and Consumer Discretionary Select Sector SPDR Fund is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| XLY | ZTS | |
|---|---|---|
52-Week High | $124.52 | $150.61 |
52-Week Low | $105.64 | $71.91 |
Market Cap | — | $30.29B |
Sector | — | Health |
Enterprise Value | — | $37.86B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XLY trades at $113.99, down 0.8% today amid bearish technical signals with 18 sell indicators versus 3 buy signals. The ETF maintains 100% analyst buy consensus despite missing key valuation metrics. Recent news highlights consumer discretionary sector opportunities, with XLY positioned as a potential sleeper ETF for Q3 2026 given resilient consumer spending trends and economic conditions.
The outlook remains cautiously optimistic with strong analyst support, though technical weakness and sector concentration risks warrant monitoring. Upside potential exists from consumer spending resilience and economic broadening, while downside risks include market volatility and inflationary pressures affecting discretionary purchases.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
